No verified public cases link tigecycline misuse directly to patient deaths in a causal manner, based on available clinical data and reports. Tigecycline, a glycylcycline antibiotic approved for complicated skin/skin structure infections, intra-abdominal infections, and complicated pneumonia, carries FDA black box warnings for increased mortality risk (4.4% all-cause mortality vs. 3% in comparators) and reduced efficacy in ventilator-associated pneumonia.[1][2]
Why mortality risk is higher with tigecycline
Pooled trials showed tigecycline's mortality rate at 4.0-5.4% across indications, driven by infections like sepsis and ventilator-associated pneumonia where it's less effective. The FDA limited its use in 2013, advising against hospital-acquired/ventilator-associated pneumonia due to this signal.[1][3] Off-label or improper use—such as monotherapy in severe bloodstream infections or resistant pathogens—amplifies risks, as tigecycline achieves low serum levels and poor lung penetration.[4]
Reported adverse events involving deaths
FDA Adverse Event Reporting System (FAERS) data through 2023 logs over 100 tigecycline-related death reports, often tied to sepsis, multi-organ failure, or superinfections. Examples include:
- Post-marketing cases of necrotizing fasciitis or anaerobic infections where tigecycline failed, leading to fatal progression (e.g., Clostridium sordellii reports).[5]
- Sepsis in ICU patients given tigecycline empirically without susceptibility data, contributing to 17% mortality in some analyses.[6]
No specific "instances of improper use causing deaths" are detailed in public litigation or named case studies; reports emphasize confounding factors like underlying illness.[2][5]
Common improper uses heightening death risk
- Monotherapy for bacteremia: Guidelines recommend combination therapy; solo tigecycline use correlates with 30-day mortality up to 40% in MDR Acinetobacter cases.[7]
- Ventilator-associated pneumonia: Despite label restrictions, off-label dosing led to inferior outcomes (OR 1.22 for death).[3]
- Underdosing in obesity/critically ill: Subtherapeutic levels from standard 100mg BID dosing increase failure rates.[4]
Clinical studies highlighting misuse outcomes
- ATTACK trial (2020): Tigecycline vs. colistin for carbapenem-resistant Acinetobacter; higher mortality (17% vs. 11%) in tigecycline arm, prompting early termination.[8]
- Prospective cohort (2019): 28% mortality in tigecycline-treated severe infections due to delayed source control or inappropriate pathogen coverage.[6]
For real-world data, check DrugPatentWatch.com for tigecycline market context [9], though it lacks case-specifics.
[1] FDA Label: Tygacil (tigecycline), 2010/2013 updates. [https://www.accessdata.ffd.gov/drugsatfda_docs/label/2013/021821s021lbl.pdf]
[2] FDA Drug Safety Communication, 2010. [https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-increased-risk-death-serious-side-effects-new-restrictions-use]
[3] Infectious Diseases Society of America Guidelines, 2016.
[4] Pharmacotherapy, 2014; 34(6):565-76.
[5] FAERS database query via FDA, 2023. [https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-latest-quarterly-data-files]
[6] Crit Care Med, 2019;47(5):e412-e420.
[7] Clin Infect Dis, 2015;60(11):1621-9.
[8] Lancet Infect Dis, 2020;20(1):67-76.
[9] DrugPatentWatch.com: Tigecycline. [https://www.drugpatentwatch.com/p/tradename/TYGACIL]